Known targets — ChEMBL curated mechanism
TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8
The experimentally established mechanism targets of Docetaxel Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A known ✓ | P04350 | 4/20 | 1.00 |
| ▸ | TUBB known ✓ | P07437 | 4/20 | 1.00 |
| ▸ | TUBA3C known ✓ | P0DPH7 | 4/20 | 1.00 |
| ▸ | TUBA1B known ✓ | P68363 | 4/20 | 1.00 |
| ▸ | TUBA4A known ✓ | P68366 | 4/20 | 1.00 |
| ▸ | TUBB4B known ✓ | P68371 | 4/20 | 1.00 |
| ▸ | TUBB3 known ✓ | Q13509 | 4/20 | 1.00 |
| ▸ | TUBB2A known ✓ | Q13885 | 4/20 | 1.00 |
| ▸ | TUBB8 known ✓ | Q3ZCM7 | 4/20 | 1.00 |
| ▸ | TUBA3E known ✓ | Q6PEY2 | 4/20 | 1.00 |
| ▸ | TUBA1A known ✓ | Q71U36 | 4/20 | 1.00 |
| ▸ | TUBA1C known ✓ | Q9BQE3 | 4/20 | 1.00 |
| ▸ | TUBB6 known ✓ | Q9BUF5 | 4/20 | 1.00 |
| ▸ | TUBB2B known ✓ | Q9BVA1 | 4/20 | 1.00 |
| ▸ | TUBB1 known ✓ | Q9H4B7 | 4/20 | 1.00 |
| ▸ | NPC1 | O15118 | 8/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 2/20 | 1.00 |
| ▸ | NOD2 | Q9HC29 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 2/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Docetaxel Anhydrous SCHEMBL19236131 | 1.00 | NPC1 (1.00) | NPC1TUBB4ATUBBTUBA3CTUBA1B | |
| Docetaxel Anhydrous SCHEMBL13524298 | 1.00 | NPC1 (1.00) | NPC1TUBB4ATUBBTUBA3CTUBA1B | |
| Docetaxel Anhydrous SCHEMBL177909 | 1.00 | NPC1 (1.00) | NPC1TUBB4ATUBBTUBA3CTUBA1B | |
| Docetaxel Anhydrous SCHEMBL22503340 | 1.00 | NPC1 (1.00) | NPC1TUBB4ATUBBTUBA3CTUBA1B | |
| Docetaxel Anhydrous SCHEMBL25052982 | 1.00 | NPC1 (1.00) | NPC1TUBB4ATUBBTUBA3CTUBA1B | |
| Docetaxel Anhydrous SCHEMBL12127070 | 1.00 | NPC1 (1.00) | NPC1TUBB4ATUBBTUBA3CTUBA1B | |
| Docetaxel Anhydrous SCHEMBL25446250 | 1.00 | NPC1 (1.00) | NPC1TUBB4ATUBBTUBA3CTUBA1B | |
| Docetaxel Anhydrous SCHEMBL21465719 | 1.00 | NPC1 (1.00) | NPC1TUBB4ATUBBTUBA3CTUBA1B | |
| Docetaxel Anhydrous SCHEMBL23134940 | 1.00 | NPC1 (1.00) | NPC1TUBB4ATUBBTUBA3CTUBA1B | |
| Docetaxel Anhydrous SCHEMBL22667521 | 1.00 | NPC1 (1.00) | NPC1TUBB4ATUBBTUBA3CTUBA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170266308-A1 | SMALL MOLECULE CONJUGATES SPECIFICALLY ACTIVATED IN TUMOR MICROENVIROMENT FOR TARGETING AND USE THEREOF | YAFEI SHANGHAI BIOLOG MEDICINE SCIENCE & TECHNOLOGY CO. LTD. (CN) | 2017-09-21 | — | — | US | disclosed |
| EP-3184540-A1 | SPECIFICALLY ACTIVATED MICROMOLECULAR TARGET COUPLING BODY IN TUMOR MICROENVIRONMENT AND USE THEREOF | Yafei Shanghai Biolog Medicine Science& Technology (CN) | 2017-06-28 | — | — | EP | disclosed |
| US-9434610-B2 | HPMA—docetaxel conjugates and uses therefore | REXAHN PHARMACEUTICALS, INC. (US) | 2016-09-06 | — | — | US | disclosed |
| US-9434610-B2 | HPMA—docetaxel conjugates and uses therefore | REXAHN PHARMACEUTICALS, INC. (US) | 2016-09-06 | — | — | US | disclosed |
| WO-2016026458-A1 | SPECIFICALLY ACTIVATED MICROMOLECULAR TARGET COUPLING BODY IN TUMOR MICROENVIRONMENT AND USE THEREOF | 亚飞（上海）生物医药科技有限公司 | 2016-02-25 | — | — | WO | disclosed |
| US-20150071872-A1 | POLYMERIC SYSTEMS FOR THE DELIVERY OF ANTICANCER DRUGS | REXAHN PHARMACEUTICALS INC (US) | 2015-03-12 | — | — | US | disclosed |
| US-8846110-B2 | Polymeric systems for the delivery of anticancer drugs | REXAHN PHARMACEUTICALS, INC. (US) | 2014-09-30 | — | — | US | disclosed |
| US-8362240-B2 | Taxol derivatives with antitumor activity | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2013-01-29 | — | — | US | disclosed |
| US-8362240-B2 | Taxol derivatives with antitumor activity | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2013-01-29 | — | — | US | disclosed |
| US-20110275841-A1 | PREPARATION OF DOCETAXEL | DR. REDDY'S LABORATORIES, INC. (US) | 2011-11-10 | — | — | US | disclosed |
| US-20110275841-A1 | PREPARATION OF DOCETAXEL | DR. REDDY'S LABORATORIES, INC. (US) | 2011-11-10 | — | — | US | disclosed |
| US-20110086111-A1 | POLYMERIC SYSTEMS FOR THE DELIVERY OF ANTICANCER DRUGS | REXAHN PHARMACEUTICALS, INC. (US) | 2011-04-14 | — | — | US | disclosed |
| US-20100197944-A1 | DOCETAXEL PROCESS AND POLYMORPHS | DR. REDDY'S LABORATORIES LIMITED (IN) | 2010-08-05 | — | — | US | disclosed |
| US-20100197944-A1 | DOCETAXEL PROCESS AND POLYMORPHS | DR. REDDY'S LABORATORIES LIMITED (IN) | 2010-08-05 | — | — | US | disclosed |
| US-20100168420-A1 | Taxol Derivatives With Antitumor Activity | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2010-07-01 | — | — | US | disclosed |
| US-20100168420-A1 | Taxol Derivatives With Antitumor Activity | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2010-07-01 | — | — | US | disclosed |
| US-20100099644-A1 | HPMA - DOCETAXEL OR GEMCITABINE CONJUGATES AND USES THEREFORE | REXAHN PHARMACEUTICALS, INC. | 2010-04-22 | — | — | US | disclosed |
| US-20090221688-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING DOCETAXEL AND A DEGRADATION INHIBITOR AND A PROCESS FOR OBTAINING THE SAME | QUIRAL QUIMICA DO BRASIL S.A. (BR) | 2009-09-03 | — | — | US | disclosed |
| WO-2009006590-A9 | DOCETAXEL PROCESS AND POLYMORPHS | REDDYS LAB LTD DR (IN) | 2009-05-07 | — | — | WO | disclosed |
| WO-2009006590-A2 | DOCETAXEL PROCESS AND POLYMORPHS | DR. REDDY'S LABORATORIES LTD. (IN) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086111-A1 | POLYMERIC SYSTEMS FOR THE DELIVERY OF ANTICANCER DRUGS | APEH, LNPEP, CPA3 | TUBB4A 611/4885TUBB 680/4885TUBA3C 345/4885 |
| US-20110275841-A1 | PREPARATION OF DOCETAXEL | XPO5, DHPS, PDS5A | TUBB4A 533/4885TUBB 677/4885TUBA3C 376/4885 |
| US-20100099644-A1 | HPMA - DOCETAXEL OR GEMCITABINE CONJUGATES AND USES THEREFORE | HPGDS, HDGF, DPYD | TUBB4A 137/4885TUBB 99/4885TUBA3C 96/4885 |
| US-20170266308-A1 | SMALL MOLECULE CONJUGATES SPECIFICALLY ACTIVATED IN TUMOR MICROENVIROMENT FOR TARGETING AND USE THEREOF | CD4, MET, TNFSF10 | TUBB4A 2573/4885TUBB 2770/4885TUBA3C 3375/4885 |
| US-20100168420-A1 | Taxol Derivatives With Antitumor Activity | TUBA4A, TUBB4A, TUBB1 | TUBB4A 2/4885TUBB 10/4885TUBA3C 16/4885 |
| US-20100197944-A1 | DOCETAXEL PROCESS AND POLYMORPHS | DCTPP1, TTPA, TALDO1 | TUBB4A 206/4885TUBB 342/4885TUBA3C 212/4885 |
| US-20150071872-A1 | POLYMERIC SYSTEMS FOR THE DELIVERY OF ANTICANCER DRUGS | APEH, LNPEP, CPA3 | TUBB4A 611/4885TUBB 680/4885TUBA3C 345/4885 |
| US-20090221688-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING DOCETAXEL AND A DEGRADATION INHIBITOR AND A PROCESS FOR OBTAINING THE SAME | PLK1, PGK1, DTYMK | TUBB4A 555/4885TUBB 177/4885TUBA3C 1143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.